Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
801-820 of 1,782 trials

Carvedilol vs. Flecainide for Ventricular Arrhythmias

We are comparing two medications to see which one better reduces abnormal heartbeats in people with idiopathic ventricular arrhythmias. The study also looks at how these treatments affect quality of life and any side effects.

Ventricular ExtrasystolesMonomorphic Ventricular TachycardiaIdiopathic Ventricular Arrhythmias6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiology

Cystic Fibrosis: Anakinra Treatment Study

We are testing the safety and effectiveness of anakinra for adults and possibly adolescents with cystic fibrosis. The study aims to see if it improves lung function and quality of life.

Cystic Fibrosis>2 yearsEfficacy phase (II)Standard MedicinesInternal MedicinePulmonology

Tranexamic Acid for Postoperative Complications in Plastic Surgery

We are studying whether applying tranexamic acid to surgical wounds can reduce re-bleeding and other complications after plastic surgery. This trial includes both men and women over 18 years old.

Healthy Participants Undergoing SurgeryMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOrthopedics and Traumatology

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Postoperative Sleep Quality: DEXSLEEP Study

We are testing whether dexmedetomidine can improve sleep and reduce fatigue in elderly patients after major surgery. This may help enhance recovery and overall well-being following surgery.

Healthy Participants Aged 60 and Older1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Benzodiazepine Dependence: Stabilizing Treatment Study

We are examining how a stable dose of benzodiazepines affects people with benzodiazepine dependence who are also receiving opioid therapy. The study looks at impacts on drug use, mental and physical health, and overall quality of life.

Benzodiazepine Dependence1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePsychiatry

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Acute Myeloid Leukemia: Gemtuzumab Ozogamicin with Chemotherapy

We are studying whether adding gemtuzumab ozogamicin to standard chemotherapy helps reduce minimal residual disease in adults with newly diagnosed acute myeloid leukemia. This research aims to improve treatment outcomes and overall survival.

Favorable-Intermediate-Risk Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Septic Shock: Levetiracetam Treatment Study

We are studying whether early treatment with levetiracetam can help patients with septic shock stay awake and alert. The trial also examines its effects on survival and overall quality of life.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicineNeurologyPulmonology

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Locally Advanced NSCLC: New Chemoradiotherapy Approach

We are studying a new FDG-PET-based treatment for patients with locally advanced non-small cell lung cancer. The goal is to see if this method is safer and more effective than the standard treatment.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Metastatic Prostate Cancer: Talazoparib and Enzalutamide Study

We are testing a combination of Talazoparib and Enzalutamide for patients with metastatic prostate cancer who have progressed after abiraterone. The study aims to evaluate its effectiveness and safety as a first-line treatment.

Metastatic Prostate CancerEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Vitamin C Treatment for Cardiac Surgery Patients

We are studying whether vitamin C can reduce inflammation and improve recovery in patients undergoing cardiac surgery. This trial compares vitamin C treatment to standard care to see which is more effective.

Cardiovascular Illness>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Inhaled Therapy for High-Risk Thoracic Surgery Patients

We are studying whether using a bronchodilator before and after surgery helps reduce lung complications in patients at high risk. This trial will also look at other health outcomes and quality of life after surgery.

Postoperative Pulmonary ComplicationsConfirmation phase (III)Standard MedicinesPartially RemotePulmonology

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology